{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:50:41Z","timestamp":1786989041376,"version":"build-2736575974"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP180725"],"award-info":[{"award-number":["RP180725"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CPRIT RP190208"],"award-info":[{"award-number":["CPRIT RP190208"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-16-004-01-CCE"],"award-info":[{"award-number":["RSG-16-004-01-CCE"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA258584"],"award-info":[{"award-number":["1R01CA258584"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5P30CA142543"],"award-info":[{"award-number":["5P30CA142543"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5RO1CA154475"],"award-info":[{"award-number":["5RO1CA154475"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA196516"],"award-info":[{"award-number":["P50CA196516"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA207091"],"award-info":[{"award-number":["U01CA207091"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.eururo.2023.02.016","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T15:19:52Z","timestamp":1678288792000},"page":"275-286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1282-056X","authenticated-orcid":false,"given":"Raquibul","family":"Hannan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark F.","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurentiu M.","family":"Pop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Pedrosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payal","family":"Kapur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelie","family":"Garant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alana","family":"Christie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Robles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Durakoglugil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon","family":"Woldu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitaly","family":"Margulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Gahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Brugarolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Timmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Cadeddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2023.02.016_b0005","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eururo.2023.02.016_b0010","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0090-4295(97)00506-2","article-title":"Increased incidence of serendipitously discovered renal cell carcinoma","volume":"51","author":"Jayson","year":"1998","journal-title":"Urology"},{"issue":"3 Pt 1","key":"10.1016\/j.eururo.2023.02.016_b0015","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1148\/radiology.170.3.2644658","article-title":"Renal cell carcinoma: earlier discovery and increased detection","volume":"170","author":"Smith","year":"1989","journal-title":"Radiology"},{"key":"10.1016\/j.eururo.2023.02.016_b0020","unstructured":"Howlader N, Noone AM, Krapcho M, et al, editors. SEER cancer statistics review, 1975\u20132017. Bethesda, MD: National Cancer Institute; April 2020. https:\/\/seer.cancer.gov\/csr\/1975_2017\/."},{"key":"10.1016\/j.eururo.2023.02.016_b0025","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.purol.2019.02.009","article-title":"Who is dying after nephrectomy for cancer? Study of risk factors and causes of death after analyzing morbidity and mortality reviews (UroCCR-33 study)","volume":"29","author":"Fontenil","year":"2019","journal-title":"Progr Urol"},{"key":"10.1016\/j.eururo.2023.02.016_b0030","first-page":"581","article-title":"Percutaneous tumor ablation versus partial nephrectomy for small renal mass: the impact of histologic variant and tumor size","volume":"73","author":"Bianchi","year":"2021","journal-title":"Minerva Urol Nefrol"},{"key":"10.1016\/j.eururo.2023.02.016_b0035","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0360-3016(95)02029-2","article-title":"A review of human cell radiosensitivity in vitro","volume":"34","author":"Deschavanne","year":"1996","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2023.02.016_b0040","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.prro.2012.08.006","article-title":"Feasibility and toxicity of hypofractionated image guided radiation therapy for large volume limited metastatic disease","volume":"3","author":"Corbin","year":"2013","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.eururo.2023.02.016_b0045","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1080\/02841860600954875","article-title":"A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma","volume":"45","author":"Svedman","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.eururo.2023.02.016_b0050","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.ijrobp.2011.02.040","article-title":"Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma","volume":"82","author":"Zelefsky","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2023.02.016_b0055","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3171\/2012.8.SPINE12303","article-title":"Single-fraction stereotactic body radiotherapy for spinal metastases from renal cell carcinoma","volume":"17","author":"Balagamwala","year":"2012","journal-title":"J Neurosurg Spine"},{"key":"10.1016\/j.eururo.2023.02.016_b0060","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bju.13811","article-title":"Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial","volume":"120","author":"Siva","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.02.016_b0065","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.ijrobp.2016.06.240","article-title":"Principal analysis of a phase Ib trial of stereotactic body radiation therapy (SBRT) for primary kidney cancer","volume":"96","author":"Siva","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2023.02.016_b0070","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ijrobp.2014.07.043","article-title":"Stereotactic ablative body radiation therapy for primary kidney cancer: a 3-dimensional conformal technique associated with low rates of early toxicity","volume":"90","author":"Pham","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2023.02.016_b0075","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.ijrobp.2013.06.218","article-title":"A phase 1 dose-escalation study of robotic radiosurgery in inoperable primary renal cell carcinoma","volume":"87","author":"McBride","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2023.02.016_b0080","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1016\/j.ijrobp.2010.07.464","article-title":"Results of a phase I Dose escalation study of stereotactic radiosurgery for primary renal tumors","volume":"78","author":"Kaplan","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2023.02.016_b0085","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.radonc.2015.08.030","article-title":"Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma","volume":"117","author":"Ponsky","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2023.02.016_b0090","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.juro.2014.08.044","article-title":"Single fraction radiosurgery for the treatment of renal tumors","volume":"193","author":"Staehler","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.02.016_b0095","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.radonc.2016.01.027","article-title":"Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: establishing a dose-response relationship","volume":"118","author":"Siva","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2023.02.016_b0100","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.radonc.2020.10.031","article-title":"Final results of a dose escalation protocol of stereotactic body radiotherapy for poor surgical candidates with localized renal cell carcinoma","volume":"155","author":"Grubb","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2023.02.016_b0105","doi-asserted-by":"crossref","first-page":"544","DOI":"10.2214\/AJR.14.14099","article-title":"Effect of stereotactic body radiotherapy on the growth kinetics and enhancement pattern of primary renal tumors","volume":"206","author":"Sun","year":"2016","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.eururo.2023.02.016_b0110","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1148\/rg.272065119","article-title":"Sequential changes after radiofrequency ablation and cryoablation of renal neoplasms: role of CT and MR imaging","volume":"27","author":"Kawamoto","year":"2007","journal-title":"Radiographics"},{"key":"10.1016\/j.eururo.2023.02.016_b0115","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0022-5347(05)00148-5","article-title":"The natural history of observed enhancing renal masses: meta-analysis and review of the world literature","volume":"175","author":"Chawla","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.02.016_b0120","doi-asserted-by":"crossref","unstructured":"Neoadjuvant SABR for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombus-Safety Lead-in Results of a Phase 2 Trial.Margulis V, Freifeld Y, Pop LM, Manna S, Kapur P, Pedrosa I, Christie A, Mohamad O, Mannala S, Singla N, Wait M, Bagrodia A, Woldu SL, Gahan J, Brugarolas J, Timmerman R, Hannan R.Int J Radiat Oncol Biol Phys. 2021 Jul 15;110(4):1135-1142. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.01.054. Epub 2021 Feb 5.","DOI":"10.1016\/j.ijrobp.2021.01.054"},{"key":"10.1016\/j.eururo.2023.02.016_b0125","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ijrobp.2007.10.059","article-title":"Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy","volume":"70","author":"Park","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2023.02.016_b0130","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijrobp.2021.09.027","article-title":"A story of hypofractionation and the table on the wall","volume":"112","author":"Timmerman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2023.02.016_b0135","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1158\/1078-0432.CCR-19-0104","article-title":"High-plex predictive marker discovery for melanoma immunotherapy-treated patients using digital spatial profiling","volume":"25","author":"Toki","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2023.02.016_b0140","doi-asserted-by":"crossref","first-page":"i555","DOI":"10.1093\/bioinformatics\/bty271","article-title":"GSEA-InContext: identifying novel and common patterns in expression experiments","volume":"34","author":"Powers","year":"2018","journal-title":"Bioinformatics"},{"key":"10.1016\/j.eururo.2023.02.016_b0145","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.juro.2009.05.035","article-title":"The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth","volume":"182","author":"Kutikov","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.02.016_b0150","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/cam4.4428","article-title":"Extent of tumor fibrosis\/hyalinization and infarction following neoadjuvant radiation therapy is associated with improved survival in patients with soft-tissue sarcoma","volume":"11","author":"Rao","year":"2022","journal-title":"Cancer Med"},{"key":"10.1016\/j.eururo.2023.02.016_b0155","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s00432-015-1974-6","article-title":"Radiation-induced fibrosis: mechanisms and implications for therapy","volume":"141","author":"Straub","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.eururo.2023.02.016_b0160","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.31156","article-title":"Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK)","volume":"124","author":"Siva","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2023.02.016_b0165","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1186\/s12885-018-4916-2","article-title":"TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney\u2014FASTRACK II","volume":"18","author":"Siva","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eururo.2023.02.016_b0170","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.euf.2019.06.002","article-title":"The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: a systematic review and meta-analysis","volume":"5","author":"Correa","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2023.02.016_b0175","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S1470-2045(22)00656-8","article-title":"5-Year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney)","volume":"23","author":"Siva","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2023.02.016_b0180","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.eururo.2006.03.021","article-title":"Efficacy of ablative high-dose-per-fraction radiation for implanted human renal cell cancer in a nude mouse model","volume":"50","author":"Walsh","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.02.016_b0185","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1002\/cncr.23896","article-title":"Cryoablation or radiofrequency ablation of the small renal mass: a meta-analysis","volume":"113","author":"Kunkle","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2023.02.016_b0190","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/1756287210366708","article-title":"Ablative therapies for renal tumors","volume":"2","author":"Ramanathan","year":"2010","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.eururo.2023.02.016_b0195","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.eururo.2012.08.062","article-title":"Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma","volume":"63","author":"Psutka","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.02.016_b0200","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.eururo.2016.08.039","article-title":"Cryoablation versus partial nephrectomy for clinical T1b renal tumors: a matched group comparative analysis","volume":"71","author":"Caputo","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.02.016_b0205","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.ijrobp.2020.06.014","article-title":"Stereotactic ablative radiotherapy for primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK)","volume":"108","author":"Siva","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2023.02.016_b0210","first-page":"3980","article-title":"Radiofrequency ablation for T1a tumors in a solitary kidney: promising intermediate oncologic and renal function outcomes","volume":"15","author":"Raman","year":"2008","journal-title":"Can J Urol"},{"key":"10.1016\/j.eururo.2023.02.016_b0215","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1590\/0100-3984.2019.0098","article-title":"Early trends and predictors of renal function following computed tomography-guided percutaneous cryoablation of a renal mass in patients with and without prior renal impairment","volume":"53","author":"Staziaki","year":"2020","journal-title":"Radiol Bras"},{"key":"10.1016\/j.eururo.2023.02.016_b0220","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.bcp.2008.06.024","article-title":"Accelerated senescence: an emerging role in tumor cell response to chemotherapy and radiation","volume":"76","author":"Gewirtz","year":"2008","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.eururo.2023.02.016_b0225","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0092-8674(00)81902-9","article-title":"Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a","volume":"88","author":"Serrano","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2023.02.016_b0230","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1101\/gad.12.19.2997","article-title":"Senescence of human fibroblasts induced by oncogenic Raf","volume":"12","author":"Zhu","year":"1998","journal-title":"Genes Dev"},{"key":"10.1016\/j.eururo.2023.02.016_b0235","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s11357-020-00183-3","article-title":"Regulation of senescence traits by MAPKs","volume":"42","author":"Anerillas","year":"2020","journal-title":"Geroscience"},{"key":"10.1016\/j.eururo.2023.02.016_b0240","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1038\/nprot.2006.339","article-title":"Clonogenic assay of cells in vitro","volume":"1","author":"Franken","year":"2006","journal-title":"Nat Protoc"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283823026258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283823026258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:13:53Z","timestamp":1759583633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283823026258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0302283823026258"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2023.02.016","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2023.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}